Skip to Content

Lucentis Approval History

Lucentis (ranibizumab) is a humanized anti-VEGF antibody fragment indicated for the treatment of neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy.

Development History and FDA Approval Process for Lucentis

Oct 14, 2016Approval FDA Approves Genentech’s Lucentis (Ranibizumab Injection) Prefilled Syringe
Feb  6, 2015Approval FDA Approves Lucentis (ranibizumab) to Treat Diabetic Retinopathy
Aug 10, 2012Approval FDA Approves Lucentis (ranibizumab injection) for Treatment of Diabetic Macular Edema (DME)
Jun 23, 2010Approval FDA Approves Lucentis (Ranibizumab Injection) for the Treatment of Macular Edema Following Retinal Vein Occlusion
Dec 30, 2005Genentech Submits Biologics License Application for FDA Review of Lucentis in Wet Age-Related Macular Degeneration

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.